The Thr190 residue is a licensing checkpoint for RIPK1 kinase activation and cytotoxicity
Abstract Receptor-interacting protein kinase 1 (RIPK1) dictates the balance between TNF-induced cell survival and death. Among the phosphorylation-dependent checkpoints that restrain RIPK1, threonine 190 (T190) is mechanistically unique: both phospho-deficient and phospho-mimetic mutations abolish kinase activity, indicating that the unmodified residue itself is required for RIPK1 activation. Despite this biochemical insight, the physiological relevance of T190 has remained unexplored due to the absence of an in vivo genetic model. To address this gap, we generated Ripk1 T190A/T190A knock-in mice. We show that the T190A mutation selectively abolishes RIPK1-dependent apoptosis, necroptosis, and pyroptosis, confers strong protection against TNF-induced systemic inflammatory response syndrome (SIRS), and fully rescues the embryonic lethality of Tbk1 −/− mice. Mechanistically, T190A specifically blocks RIPK1 autophosphorylation at Ser166, establishing T190 as a non-redundant licensing checkpoint that fundamentally distinguishes it from conventional inhibitory phosphorylation sites.
Authors
- Chenglong Wang (ORCID: https://orcid.org/0000-0002-7103-7850)
- Daichao Xu (ORCID: https://orcid.org/0000-0002-3286-4968)
- Sisi Luan (ORCID: https://orcid.org/0000-0002-9144-9537)
- Yuanxin Yang (ORCID: https://orcid.org/0009-0001-2504-4013)
Institutions
- Beijing Tongren Hospital (CN)
- Capital Medical University (CN)
- Chinese Academy of Sciences (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Plastic Surgery Hospital (CN)
- Shanghai Institute of Organic Chemistry (CN)
Publication Details
- Journal
- Cell Death and Disease
- Published
- 2026-11-17
- DOI
- https://doi.org/10.1038/s41419-026-09409-2
- Primary Topic
- Cell death mechanisms and regulation
- Type
- article
- Field-Weighted Citation Impact
- 0.00